MediWound to Report First Quarter 2026 Financial Results
Rhea-AI Summary
MediWound (Nasdaq: MDWD) will release first quarter 2026 financial results for the period ended March 31, 2026 on Wednesday, May 27, 2026. A conference call and live webcast will follow at 8:30 a.m. Eastern Time for management commentary and a corporate update.
Dial-in numbers and webcast access are provided; an archived replay will be available on the company’s Investors website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MDWD
On the day this news was published, MDWD declined 0.58%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MDWD is modestly lower while several biotech peers in the sector list show single-digit gains, and scanner data flags TRDA with a sharp -48.16% move on its own catalysts. This mix points to stock-specific positioning rather than a coordinated sector swing.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings date notice | Neutral | +0.9% | Announced date and time for Q4 and full-year 2025 earnings call. |
Prior earnings date scheduling news for MDWD was followed by a modest positive move of 0.88%, suggesting neutral-to-slightly-positive reactions when call dates are announced.
Recent news for MDWD has focused on strategic and financial milestones. In early March 2026, the company reported full-year 2025 results with $17.0M revenue and $53.6M cash and reaffirmed multi-year revenue guidance. Subsequent updates highlighted a BARDA-linked NexoBrid contract via Vericel and new EscharEx data presentations. The current first-quarter 2026 earnings date announcement continues this cadence of regular financial and clinical communication.
Historical Comparison
In the past, MDWD issued one similar earnings date announcement, which saw an average 0.88% move, indicating historically muted but slightly constructive reactions to this type of news.
The company continues a pattern of pre-announcing financial reporting dates with accompanying conference calls and webcasts, maintaining consistent investor communication around quarterly and annual results.
Market Pulse Summary
This announcement schedules MediWound’s first-quarter 2026 financial results for May 27 with a conference call at 8:30 a.m. Eastern. In recent months, investors have seen key milestones including full-year 2025 results, reaffirmed multi-year revenue guidance, and BARDA-related NexoBrid developments. Ahead of the call, attention will likely center on revenue growth versus $17.0M in 2025, cash trends, and progress on EscharEx and NexoBrid execution.
AI-generated analysis. Not financial advice.
MediWound to Report First Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 27th at 8:30 a.m. Eastern Time
YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the first quarter ended March 31, 2026 on Wednesday, May 27, 2026.
Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.
Conference Call & Webcast Details
Toll-Free: 1-844-676-8833
Israel: 1-809-212373
International: 1-412-634-6869
Webcast: Click HERE
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.
For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).
MediWound Contacts:
Hani Luxenburg Daniel Ferry
Chief Financial Officer Managing Director
MediWound Ltd. LifeSci Advisors, LLC
ir@mediwound.com daniel@lifesciadvisors.com
